



Michael Wolff Jensen resigns from the Vicore board of directors and is replaced by Jacob Gunterberg as chairman of the board up until the annual general meeting in May 2022

Gothenburg, March 23, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), today announces that Michael Wolff Jensen has resigned from the board of directors.

Michael Wolff Jensen, who has been the chairman of the board of directors of Vicore Pharma Holding AB (publ) since 2020, has today informed the board of directors of his resignation as chairman and member of the board of directors due to personal reasons.

Michael will leave Vicore’s board of directors with immediate effect. For the period of time up until the annual general meeting in May 2022, the board has today elected Jacob Gunterberg as new chairman of the board of directors.

“On behalf of the board and the shareholders, I would like to express a sincere thank you to Michael for his work as chairman of Vicore’s board”, says Jacob Gunterberg, newly elected chairman of the board.

For further information, please contact:

Nina Carlén, Chief Administrative Officer

Phone: +46 76-390 94 04

E-mail: nina.carlen@vicorepharma.com

Jacob Gunterberg, Chairman of the board

Phone: +46 70 975 98 58

E-mail: jacob.gunterberg@gmail.com

This information was submitted for publication on March 23, 2022 at 21:55 CET.

About Vicore Pharma Holding AB (publ)

Vicore is a clinical-stage pharmaceutical company focused on developing innovative medicines in severe lung diseases where the Angiotensin II type 2 receptor (AT2R) plays an important role. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF), pulmonary artery hypertension (PAH) and COVID-19. VP02 is a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2 receptor agonists. VP04 develops a clinically validated digital therapeutic for IPF patients.

The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see www.vicorepharma.com.